Platelet activation by the stable endoperoxide analogue U46619 is mediated largely by ADP released from platelet-dense granules. Polymorphonuclear leukocytes (PMNs) endowed with ecto-ADPase activity may operate as antiaggregatory cells in platelet aggregation induced by U46619. Unstimulated PMNs were effective in reducing aggregation when platelets were stimulated by threshold concentrations of U46619, whereas at higher concentrations of the stimulus, PMN activation is required. Evidence that the inhibition was mediated by PMN ecto-ADPase activity was obtained by high-performance liquid chromatography analysis, indicating that PMNs were able to efficiently metabolize platelet-active ADP into AMP. Moreover, PMN-derived supernatants were able to inhibit platelet aggregation, suggesting that under this circumstance the inhibition was exerted by an uncharacterized, releasable ADPase activity. This study supports the hypothesis that, besides nitric oxide and hydrogen peroxide, ADPase activity may represent another PMN-mediated pathway capable of regulating platelet activity in areas of reduced blood flow, such as those found in conditions of myocardial ischemia. 
P revious studies reported that polymorphonuclear leukocytes (PMNs) reduced the activity of washed platelets 1 -2 as well as their aggregation in whole blood 1 and platelet-rich plasma. 3 PMNs inhibit platelet activity either by the release of nitric oxide 4 " 6 or by the generation of hydrogen peroxide during the respiratory burst. 7 " 9 In addition, ecto-ADPase activity exerted by PMNs may reduce platelet activation by reducing the extracellular concentration of plateletactive adenosine diphosphate. 10 These findings may be of physiopathological interest, because platelets and leukocytes may accumulate in vivo in areas of reduced blood flow, such as those found during conditions of myocardial ischemia.
11
" 13 The reciprocal interactions that may develop between these cells (for review, see Reference 14) may condition the outcome of the disease.
The purpose of this study was to further investigate the role played by PMN ADPase activity on platelet activation. The mechanism by which local levels of platelet-active ADP are regulated is of particular interest because ADPase activity is commonly shared by several cells that participate in the pathogenesis of both thrombotic and atherosclerotic processes, such as endothelial cells, 15 " 17 erythrocytes, 18 and platelets. 19 
Methods

Chemicals
Prostacyclin (PGI 2 ), Af-formyl-L-methionyl-L-leucyl-Lphenylalanine (fMLP), adenosine-5 '-triphosphate (ATP), adenosine-5'-diphosphate (ADP), adenosine-5'-monophosphate (AMP), adenosine, a,/3-methyleneadenosine 5'-diphosphate, P1 ,/ >5 -di(adenosine-5')pentaphosphate, levamisole, /3-glycerophosphate, sodium azide, bovine serum albumin (BSA), tris(hydroxymethyl)aminomethane (Tris), and Af-2-hydroxyethylpiperazine-Af'-2-ethanesulfonic acid (HEPES) were purchased from Sigma Chemical Co. (St. Louis, Mo.); dextran T 500 and Ficoll-Hipaque were from Pharmacia Fine Chemicals (Uppsala, Sweden); 15(S)hydroxy-ll(epoxymethano)prosta-(5Z,13£)-dienoic acid (U46619) was from The Upjohn Co. (Kalamazoo, Mich.); collagen was from Mascia Brunelli (Milan, Italy); adenosine deaminase, /3,-y-methyleneadenosine 5'-triphosphate, superoxide dismutase, and catalase were from Boehringer Mannheim (Mannheim, FRG); and the /3-thromboglobulin radioimmunoassay kit was from Amersham (Bucks, UK); all other materials were pure reagent grade. Tyrode's buffer (pH 7.4) containing (in mmol/L) NaCl 136, NaHCO 3 11.9, KC1 2.65, NaH 2 PO 4 0.42, dextrose 5, MgCl 2 1, CaCl 2 2, and HEPES 3 was supplemented with 3.5 mg/mL BSA. weeks were anticoagulated with one part of ACD (1.5% citric acid, 2.5% trisodium citrate, and 2.0% dextrose). Washed platelets (3xlO 8 /mL) were prepared as described 20 except that PGI 2 was added to the first and second washing fluids at a final concentration of 0.2 /nmol/L. PMNs were isolated from platelet-rich plasmadepleted blood by dextran sedimentation followed by centrifugation on a Ficoll-Hipaque gradient and hypotonic lysis (30 seconds in distilled water) of erythrocytes. 21 PMN supernatants were obtained as follows. PMNs (5xlO 7 /mL) were incubated for 10 minutes at 37°C under constant stirring in the presence of fMLP (10~1 0 to 10" 6 mol/L) or the equivalent volume of buffer. Samples were then centrifuged at 12,000g for 1 minute, and the supernatants were subsequently added to platelet suspensions for bioassay.
Aggregation Studies Using Mixtures of Platelets With PMNs or PMN-Derived Supernatants
Platelets (3xlO 8 /mL) alone or mixed with either resting or fMLP-stimulated PMNs (10 7 /mL) in a final volume of 600 ixL were preincubated in a Chrono-Log aggregometer (model 550, Hawertown, Pa.) for 4 minutes at 37°C before addition of the stimulus. In a series of experiments, platelets were preincubated with supernatants derived from either unstimulated or fMLPactivated PMNs (30-250 /xL). Aliquots (10 /xL) were taken before and 3 minutes after addition of stimulus, and platelet aggregation was quantified as the fall in single-platelet count measured with a platelet analyzer (Baker Instruments, Allentown, Pa.). In a set of experiments, aggregation was studied on platelet-rich plasma obtained from blood anticoagulated with 3.8% trisodium citrate. The concentration of U46619 that caused a 75% drop in platelet count 3 minutes after addition of the stimulus was considered to be the threshold aggregating concentration (TAC). At the end of the incubation time, samples were immediately centrifuged at 4°C (12,000g for 1 minute), and ice-cold perchloric acid was immediately added to the resulting supernatants (0.66N) for adenine nucleotide extraction. /3-Thromboglobulin release was quantified as previously described. 1 
Effect of PMNs on ADP Metabolism
ADP (100 /xmol/L) was exposed for 5 minutes at 37°C to either PMNs (0.3-1 x 10 7 /mL) or supernatants of 10~6 mol/L fMLP-stimulated PMNs (5xlO 7 /mL). Samples were then centrifuged at 4°C (12,000g for 1 minute), and supernatants were analyzed by high-performance liquid chromatography (HPLC) after extraction.
HPLC Analysis
Supernatants (500 /xL) were mixed with 300 iiL of ice-cold perchloric acid (0.66N) and subsequently centrifuged at 4°C (12,000g for 10 minutes). Aliquots of the deproteinated supernatants were neutralized (pH 7) by addition of Tris (0.1 mol/L) KOH (10%) and centrifuged (12,000g for 10 minutes), and the supernatants obtained were stored at -80°C until HPLC. Neutralized extracts (10 /xL) were analyzed for adenine nucleotide content by reverse-phase HPLC (detection limit, 2-5 pmol/10 iiL) as previously described. 
Results
PMNs Inhibit Platelet Aggregation by Reducing Agonist-Induced ADP Release
Platelet (3xlO 8 /mL) aggregation was induced by U46619 at TACs (150-300 nmol/L) and at threefold higher concentrations (450-900 nmol/L). When PMNs (10 7 /mL) were present during platelet activation by TAC of U46619, a significant inhibition of platelet aggregation was observed ( Figure 1 , panel A). Similar results were obtained when platelets were stimulated by collagen (0.5-3 Mg/mL). In the presence of PMNs (10 7 /mL), collagen-induced platelet aggregation (85 ±7% of aggregated platelets) was reduced to 12 ±6% (mean±SEM of three separate experiments).
The influence of plasma on PMN-dependent inhibition was tested by experiments performed with platelet-rich plasma. Platelet aggregation induced by either collagen (0.5 /xg/mL) or ADP (2 jtxmol/L) was 77±5% and 82±3%, respectively, whereas in the presence of PMNs it was 21 ±4% and 23±3%, respectively (mean±SEM of three separate experiments).
As shown in Figure 1 (panel B), PMN-dependent inhibition was overcome when washed platelets were exposed to higher U46619 concentrations. When mixed cell suspensions were exposed to fMLP (10~1 0 to 10" 6 mol/L) for 4 minutes before addition of U46619 (450-900 nmol/L), an inhibition of aggregation was noted that was related to the fMLP concentration used (Figure 1 , panel B).
Like aggregation, the release from both platelet a-granules and dense bodies was also reduced by resting PMNs. As shown in Figure 2 (panel A), release of /3-thromboglobulin (7.8±0.9 jug/mL) from platelets (3xl0 8 /mL) activated by TACs of U46619 was reduced sixfold. Adenine nucleotide release, monitored in parallel by HPLC analysis, was reduced by PMNs to a similar extent. In the presence of PMNs, the amounts of ATP and ADP released from activated platelets (2.6±0.3 and 2.7±0.7 /xmol/L, respectively) were greatly reduced (Figure 2, panel B) , whereas similar levels of AMP were measured either in the absence or presence of PMNs (1.5±0.2 and 1.8±0.2 /zmol/L, respectively). Finally, neither adenosine nor other nucleotide metabolites were detected in these experiments.
These findings suggest that reduced ADP availability, possibly by PMN ecto-ADPase activity, 23 impairs the largely ADP-dependent platelet activation induced by U46619. 24 -26 To characterize the nature of the inhibitory activity, we performed a series of experiments with specific inhibitors of ecto-ADPase, 10 5'-nucleotidase, 27 and phosphatase activity. 28 The effect of 100 ^mol/L )3,ymethyleneadenosine 5'-triphosphate, 2.5 mmol/L a,J3-methyleneadenosine 5'-diphosphate, and 100 jtmol/L levamisole was tested on U46619-induced platelet aggregation in platelet and platelet-PMN suspensions ( Table 1 ). The inhibitory activity of PMNs (10 7 /mL) on platelet aggregation was prevented by the ecto-5'-nucleotidase inhibitor a,/3-methyleneadenosine 5'-diphosphate used at a concentration reported to inhibit ectoADPase activity as well. 27 Moreover, PMN inhibition was not prevented by adenosine deaminase used at concentrations (0.3-1.25 /xg/mL) that did not in themselves affect platelet aggregation induced by U46619. In the presence of PMNs, aggregated platelets were 12±2% and 18±2% in the absence or presence of adenosine deaminase, respectively (mean±SEM of three separate experiments). Finally, the inhibition exerted by PMNs was not substantially modified in the presence of either 25 units/mL superoxide dismutase or 1,000 units/mL catalase (data not shown).
PMNs efficiently metabolized exogenous ADP (100 jiimol/L) preferentially to AMP, as shown in the representative HPLC chromatograms (Figure 3) . ADP metabolism was dependent on the number of PMNs with maximal effect reached when ADP was incubated (5 minutes at 37°C) with PMNs at a cell concentration of /mL) were exposed to 10" 8 mol/L fMLP.
FIGURE 4. Histogram showing reverse-phase high-performance liquid chromatography (RP-HPLC) analysis of ADP metabolism by polymorphonudear leukocytes (PMNs
PMN Supernatants Retain Inhibitory Activity
Platelet aggregation induced by TAC of U46619 was dose-dependently inhibited by supernatants (30-250 /xL) derived from unstimulated PMNs. As shown in Figure 5 , at threefold higher U46619 concentrations, 250 ju,L of the supernatant inhibited platelet aggregation by 40%. Moreover, supernatants (30-250 /AL) derived from fMLP-stimulated PMNs inhibited platelet aggregation induced by higher concentrations of U46619 in a concentration-dependent manner. The inhibitory effect of supernatants was related to the concentration of fMLP used to activate PMNs ( Figure 6 ). 
(solid circles) mol/L N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP)-stimulated polymorphonudear leukocytes (PMNs). Platelet aggregation was quantified as the fall in single-platelet count as described in "Methods." Results are mean±SEM of four different experiments.
We then evaluated whether the inhibition exerted by PMN-derived supernatants might be related to enhanced ADP metabolism, since ADPase activity is located not only in the plasma membrane but also in both PMN granules and the cytoplasm. 23 Aliquots of supernatants of fMLP (10~6 mol/L)-activated PMNs exposed to ADP (100 /xmol/L) were either analyzed by HPLC for ADP metabolism or used as a stimulus for platelet aggregation in plasma.
After incubation with fMLP-activated PMN supernatants, ADP recovery was reduced by 40% (Table 2) . ADP was converted by about 20% into AMP and 18% into ATP. Adenine nucleosides were not detected by HPLC analysis in PMN-derived supernatants. Smaller amounts of ADP (10 jitmol/L) were metabolized by PMN supernatants solely to AMP (data not shown). However, PMN-derived supernatants were unable to convert 100 /xmol/L of either AMP or adenosine. Results obtained indicated that AMP recovery was 85.6±3.1 and 85.8±2.2 /xmol/L when incubated with buffer or PMN supernatant, respectively. Adenosine recovery was 98.3±0.2 and 98.1 ±0.5 jumol/L when incubated with buffer or PMN supernatant, respectively (mean±SEM of two separate experiments). Finally, HPLC analysis pointed out that ADP conversion (to ATP and AMP) was also caused by PMN supernatants treated with 100 fimo\/L /3,y-methyleneadenosine 5'-triphosphate, 1 mmol/L levamisole, 10 mmol/L /3-glycerophosphate, 1,000 units/mL catalase, and 10 mmol/L NaN 3 (data not shown). Moreover, ATP generation was prevented by treatment of PMN supernatant with 10 [imolfL of the adenylate kinase inhibitor 18 /"j/^-ditadenosine-S^-pentaphosphate (15.7+1.5 versus 3.6±1.8 /xmol/L of ATP generated in the absence and presence of the inhibitor, respectively; mean±SEM of three separate experiments).
Aliquots of ADP, previously incubated with either buffer or PMN supernatants, were bioassayed for their ability to induce platelet aggregation in platelet-rich plasma. As shown in Figure 7 , ADP exposed to PMN supernatants induced platelet aggregation to a lesser extent than ADP exposed to buffer. Platelet aggregation induced by supernatant-treated ADP (final concentration, 2-4 ju,mol/L) was reduced by 45±5% compared with buffer-treated ADP. Finally, ADP exposed to heat-treated supernatants (20 minutes at 100°C) induced platelet aggregation similar to that induced by ADP exposed to either boiled or untreated buffer.
Discussion
In this study, we provide evidence that PMNs inhibit the platelet response to the stable endoperoxide analogue U46619. They achieve that effect by ADPase activity that metabolizes platelet-derived ADP. Release of this nucleotide is considered the key event in fibrinogen binding and the subsequent platelet aggregation induced by U46619. Indeed, the inhibition of ADP activity, obtained either by enzymatically removing the nucleotide or by receptor antagonism, causes a substantial reduction of the platelet response to U46619. As shown in Figure 2 , both the U46619-induced platelet aggregation and release reaction were inhibited in the presence of PMNs. Analysis by HPLC indicated that, upon activation, platelets (3xlO 8 /mL) released both ATP and ADP from their dense bodies. However, the release of both adenine nucleotides is markedly reduced in the presence of PMNs, whereas similar AMP levels were detected either in the absence (1.5±0.2 /imol/L) or presence (1.8±0.2 p,mol/L) of PMNs. These findings suggest that the positive feedback mechanism of platelet activation, mediated by the agonist-induced ADP release, may be suppressed, possibly by PMN ecto-ADPase activity.
U46619-induced platelet aggregation was strongly inhibited by the specific ecto-ADPase inhibitor /3,ymethyleneadenosine 5'-triphosphate (Table 1) . Further evidence for the role played by PMN ecto-ADPase in inhibition of the platelet response came from experiments performed with a,/3-methyleneadenosine 5'-diphosphate. This compound, besides inhibiting ecto-5'-nucleotidase activity, also inhibits PMN ecto-ADPase activity, with consequent blocking of ADP metabolism, as previously described. 27 The inhibition exerted by PMNs was prevented in the presence of a,)8-methyleneadenosine 5'-diphosphate. Moreover, we performed experiments with levamisole to exclude the possibility that PMNs may metabolize ADP by nonspecific phosphatases. However, U46619-induced platelet aggregation was inhibited by PMNs even in the presence of 100 /umol/L levamisole, suggesting that PMNs metabolize platelet-derived ADP specifically by their membraneassociated ecto-ADPase activity.
The inhibition exerted by PMNs could be overcome, however, when platelet aggregation was induced by threefold higher U46619 concentrations. These findings suggest that the activity of membrane ecto-ADPase may be insufficient to metabolize the excess of released ADP. Under these conditions, platelet aggregation may be inhibited only by stimulated PMNs (Figure 1) , which expose to their extracellular surface ADPase activity associated with the membrane of specific granules. 23 ' 29 Exogenous ADP was efficiently converted by PMNs preferentially into AMP. These data are in accordance with previous findings reporting that leukocytes contribute to nucleotide metabolism in blood mainly by either their ecto-ADPase or ecto-ATPase activities and not by ecto-5'-nucleotidase activity. 10 In the present study, we provide evidence that PMNs release an activity that both inhibits U46619-induced platelet aggregation ( Figure 5 ) and converts ADP (Table 2). This activity, not yet characterized, specifically metabolized ADP, since equimolar concentrations of AMP and adenosine were not metabolized by PMN supernatants. Furthermore, this activity retained its ability to metabolize ADP in the presence of inhibitors of either ecto-ADPase or phosphatase activity as well as in the presence of scavengers of stable metabolites of the PMN oxygen burst.
It is noteworthy that PMN supernatants may generate ATP from exogenous ADP, suggesting that PMNs release adenylate kinase activity. ATP generation was measured only when supernatants were exposed to 100 tmol/L ADP and was prevented by treatment of PMN supernatant with 10 /xmol/L of the adenylate kinase inhibitor /"j/^-d^adenosine-S^-pentaphosphate.
The findings that the inhibitory activity was retained in PMN-derived supernatants and was exerted by activated PMNs suggest that nitric oxide may not be involved. Indeed, nitric oxide has a short life span 30 and can be inactivated by superoxide anion released from activated PMNs. 31 - 32 Results of this study also suggest that metabolites of the PMN oxygen burst (superoxide anion and hydrogen peroxide) may not be involved in the PMN-dependent inhibition of platelet response, since PMN-dependent inhibition was also effective in the presence of superoxide dismutase and catalase. In addition, platelets may efficiently consume hydrogen peroxide by their glutathione cycle. 33 In conclusion, in this study we provide evidence that PMNs may reduce platelet response both by their ecto-ADPase and by a not-yet-characterized releasable ADPase activity.
The possibility that PMNs become inhibitors of platelet activation is of considerable physiopathological interest. Under these conditions, PMNs may dampen the uncontrolled platelet activation either by releasing inhibitory substances 4 -9 or by ecto-ADPase activity.
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Pharmacological studies performed to select antithrombotic substances should take into consideration this protective effect exerted not only by PMNs but also by endothelial cells, 15 " 17 erythrocytes, 18 and platelets themselves. 19 Finally, the results reported in this study provide further evidence that complex interactions take place between platelets and PMNs 14 and emphasize the concept of thrombosis and atherosclerosis as multicellular processes. 34 
